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Abstract: Pentavalent technetium-99m dimercaptosuccinic acid (
99mTc-(V)DMSA) is a tumor-seeking agent which was 
introduced to evaluate, image, and manage many types of cancers. In this review, the beginning of, and the most recent 
applications of using this agent was appraised. The relation with tumor cell detection and proliferation was reported and 
several mechanisms of uptake of 
99mTc-(V)DMSA in tumor cells are described.
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Introduction
Recently attempts have been made to ﬁ  nd a more accurate and speciﬁ  c radioactive tracer to image the 
proliferative activity of various types of cancers, including breast cancer. 
18F-ﬂ  urodeoxy glucose 
(
18F-FDG) positron emission tomography (PET), 
18F-ﬂ  urothymidine (
18F-FLT), and deoxyuridine has 
shown unclear results (Rasey et al. 2002; Toyohara et al. 2002; Buck et al. 2002). Pentavalent technetium-
99m dimercaptosuccinic acid (
99mTc-(V)DMSA) is a new tumor-seeking agent, which was introduced 
to evaluate, image, and manage medullary carcinoma of the thyroid (Ohta et al. 1984; Clarke et al. 
1988). 
99mTc-(V)DMSA uptake showed its presence and efﬁ  cacy in detecting many other types of 
cancers; such as head and neck, in particular squamous cell carcinoma, and soft tissue tumors (Ohta 
et al. 1988; Watkinson et al. 1989), breast (Papantoniou et al. 2002; Kashyap et al. 1992), brain (Hirano 
et al. 1997), lung (Hirano et al. 1995; Atasever et al. 1997), bone (Lam et al. 1997), and in particular, 
for metastasis and high-grade tumors (Kiratli et al. 1998). However in patients with carcinomas of the 
liver and gastrointestinal tract, malignant melanoma and lymphoma, the role of 
99mTc-(V)DMSA was 
absent (Ohta et al. 1988). Physiological uptake has been evidenced in the kidneys, nasal mucosa, lac-
rimal glands and blood pool such as in the heart and vessels. Uptake of 
99mTc-(V)DMSA was also 
reported as normal distribution in the pituitary gland (Watkinson et al. 1990). It’s uptake in the breasts 
has often been noted. Nakamoto et al. (1997) reported that female breasts should be included in the 
normal biodistribution of 
99mTc-(V)DMSA and should not be considered as pathological.
99mTc-(V)DMSA has a very high afﬁ  nity for various tumors and increased uptake in tumors, but the 
mechanism of 
99mTc-(V)DMSA uptake in tumors is still not fully elucidated. A working hypothesis 
based on the metal-complex equilibrium has anticipated the pH sensitive character of 
99mTc-(V)DMSA. 
This character was suggested to be one of the factors that affected its accumulation in cancer cells 
(Horiuchi et al. 1998a).
Factually, tumours are well known to be more acidic than normal cells (Tannock and Rotin, 1989), 
in vivo 
99mTc-(V)DMSA uptake was correlated to the lowering of pH of tumors by glucose administration 
using Ehrlich ascites tumor cells (EATC)-bearing mice (Horiuchi et al. 1998b). The study found evi-
dence of correlation between the 
99mTc-(V)DMSA uptake, which reﬂ  ects the tumor acidosis, and the 
14C-deoxyglucose (
14C-DG) uptake, which reﬂ  ects the tumor glycolysis and viability in EATC-bearing 
mice. Horiuchi et al. (1998b) reported that 
99mTc-(V)DMSA uptake by tumors was related to glucose-
mediated acidosis, and this may reﬂ  ect tumor cell viability. However, this was only reported by one 
study and in one type of cell lines (EATC) in vivo. This EATC also belongs to well-differentiated cells 
with very rapid growth rate and capacity of high aerobic glycolysis (Bustamante et al. 1981), and there-
fore it can not reﬂ  ect the accurate mechanism of 
99mTc-(V)DMSA uptake by tumors.
One study suggested that 
99mTc-(V)DMSA uptake by breast tumors is related to proliferative activ-
ity in breast, which is directly related to tumor grade (Papantoniou et al. 1999). In addition, Papantoniou 
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et al. (2001) reported that 
99mTc-(V)DMSA uptake 
by breast tumors and several breast lesions is 
related to the mitotic activity and the cellular pro-
liferation of breast tumors or lesions. Recently a 
strong correlation between 
99mTc-(V)DMSA uptake 
and cellular proliferation, as measured by Ki-67 
expression (Ki-67, a monoclonal antibody that 
recognizes a labile epitope on a nuclear antigen 
expressed in cycling cells but not quiescent cells 
(Sawhney and Hall, 1992) was demonstrated 
(Papantoniou et al. 2004; Papantoniou et al. 2005). 
Papantoniou et al. (2004) showed that the prolif-
erative activity is a major independent factor affect-
ing 
99mTc-(V)DMSA uptake in breast cancer as 
determined by Ki-67 expression and suggested that 
99mTc-(V)DMSA uptake can be of clinical signiﬁ  -
cance as an in vivo indicator of cell proliferation.
One in vitro study showed that 
99mTc-(V)DMSA 
uptake in cancer cell lines (human breast cancer; 
MCF-7, human glioblastoma multiform; G152,   
human ﬁ  brosarcoma; HT1080, lung adenocarcinoma; 
A549, human amelanomic melanoma; M3DAU, and 
grade III human glioblastoma; U-87-MG) is closely 
related to proliferation rate and focal adhesion kinase 
(FAK). Because proliferation rate and FAK are linked 
to cancer progression, Denoyer et al. (2005) 
assumed that in vivo 
99mTc-(V)DMSA uptake reﬂ  ects 
tumor aggressiveness and that 
99mTc-(V)DMSA 
uptake could provide clinicians with preoperative 
information not always obtainable by mammography.
In addition, its mechanism of uptake is thought 
to be due to the structural similarity between 
99mTc-
(V)DMSA core (phosphate-like ion TcO4 
−3) and 
phosphate (PO4 
−3) anion as taken by some cancer 
cells (Yokoyama and Saji, 1980; Wulfrank et al. 
1989). 
99mTc-(V)DMSA was originally designed 
as a metabolic mimic of phosphate, able to localize 
in cancer cells by supposed hydrolysis of the pen-
tavalent DMSA complex within cancer cells to 
produce the phosphate-like ion TcO4 
−3 (Horiuchi 
et al. 1986; Yokoyama and Saji, 1980; Yokoyama 
et al. 1981; Yokoyama et al. 1985), then the hydro-
lysis of TcO4 
−3 and the subsequent metabolism or 
whatever mechanism starts in the cancer cells. The 
possible involvement of phosphate anion in 
99mTc-
(V)DMSA uptake by tumors was conﬁ  rmed by the 
inhibition of the uptake of 
99mTc-(V)DMSA in the 
presence of phosphate ion (Lam et al. 1996).
Phosphate ion carries a negative charge, and so 
it is weakly accumulated in the cytosol by simple 
diffusion. However, it enters cells via three differ-
ent types of NaPi co-transporters: type I NaPi 
co-transporters or NPT1 in humans, expressed in 
liver and kidney (Ghishan et al. 1993; Li and Xie, 
1995), type II NaPi co-transporters (NPT2 in 
humans), expressed in brain (Hisano et al. 1997), 
osteoclasts (Gupta et al. 1996), lung (Magagnin 
et al. 1993), small intestine and proximal tubes 
(Hilfiker et al. 1998), and type III NaPi co-
transporters, which are a family of cell surface 
receptors for the Gibbon ape leukaemia virus 
(GALV) (Kavanaugh and Kabat,    1996). These 
receptors are highly related to phosphate cotrans-
porters (PiT1 in humans). This protein family is 
found in several organs and many tumor-forming 
tissues (Kavanaugh and Kabat, 1996; Kavanaugh 
et al.1994; Johann et al. 1992; Miller and Miller, 
1994; Uckert et al. 1998).
One study by Palmedo et al. (1996; 2000) dem-
onstrated that 
99mTc-(V)DMSA is a marker of phos-
phate transport and 
99mTc-(V)DMSA enters a cancer 
cell line model speciﬁ  cally via type III NaPi co-trans-
porters (PiT1) (Denoyer et al. 2004). This was 
recently demonstrated by Denoyer et al. (2004), by 
comparing 
99mTc-(V)DMSA and phosphate uptake 
kinetics in three cancer cell lines (human breast can-
cer; MCF-7, human glioblastoma multiform; G152, 
and human osteosarcoma; MG-63) and showed that 
99mTc-(V)DMSA uptake is speciﬁ  cally mediated by 
PiT1 in cancer cells. From this study, 
99mTc-(V)DMSA 
uptake can be assumed to be cell speciﬁ  c, because 
MCF-7 and G152 cancer cell lines exhibited the same 
99mTc-(V)DMSA uptake, whereas MG-63 cancer cell 
line showed the highest phosphate accumulation and 
the lowest 
99mTc-(V)DMSA uptake.
Conclusion
In this review, 
99mTc-(V)DMSA capability to detect 
cancer non invasively was reported. Several studies 
proposed the mechanism of  
99mTc-(V)DMSA uptake 
that might be involved by cancer cells. In addition, 
some studies reported its relation to cancer cell 
proliferation and this uptake might be used as a 
proliferation marker in cancer cells. However, until 
now, no strict mechanism has been fully clariﬁ  ed.
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